Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

126 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Contribution of measurable residual disease status to prediction accuracy of relapse and survival in adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation.
Rodríguez-Arbolí E, Othus M, Orvain C, Zarling LC, Sandmaier BM, Milano F, Schoch G, Davis C, Deeg HJ, Appelbaum FR, Storb R, Walter RB. Rodríguez-Arbolí E, et al. Among authors: orvain c. Haematologica. 2023 Jan 1;108(1):273-277. doi: 10.3324/haematol.2022.281631. Haematologica. 2023. PMID: 36134457 Free PMC article. No abstract available.
Implementation of a new blood cultures sampling strategy in patients receiving intensive chemotherapy for acute leukemia and/or hematopoietic cell transplantation.
Declerck C, Giltat A, Boutemy R, Brisset-Dheilly M, Pelhatre A, Hunault-Berger M, Kempf M, Kouatchet A, Mahieu R, Tanguy-Schmidt A, Orvain C. Declerck C, et al. Among authors: orvain c. Leuk Lymphoma. 2023 Jun;64(6):1204-1207. doi: 10.1080/10428194.2023.2196595. Epub 2023 Apr 13. Leuk Lymphoma. 2023. PMID: 37052331 No abstract available.
Comparison of efficacy and toxicity according to etoposide and cytarabine dosing in BEAM conditioning followed by autologous stem cell transplantation in Hodgkin lymphoma.
Vély A, Couturier MA, Delepine P, Le Calloch R, Ertault M, Gastinne T, Plichon C, Lebreton A, Lester MA, Larhantec G, Cormier N, Fouquet S, Houot R, Tanguy-Schmidt A, Hunault-Berger M, Orvain C. Vély A, et al. Among authors: orvain c. Leuk Lymphoma. 2023 Dec;64(13):2178-2187. doi: 10.1080/10428194.2023.2251073. Epub 2023 Aug 24. Leuk Lymphoma. 2023. PMID: 37615123
Clinico-biological features, treatment and prognosis of primary myeloid sarcoma: A French retrospective multi-centric observational study.
Belhadj M, Burroni B, Kosmider O, Willems L, Temple M, Bertoli S, Orvain C, Dumas PY, Berthon C, Gabellier L, Marcais A, Raffoux E, Pautas C, Genthon A, Decroocq J, Birsen R, Tamburini J, Bouscary D, Contejean A. Belhadj M, et al. Among authors: orvain c. Br J Haematol. 2023 Sep;202(6):e50-e53. doi: 10.1111/bjh.18961. Epub 2023 Jul 4. Br J Haematol. 2023. PMID: 37403204 No abstract available.
Efficacy of haematopoietic stem cell boost as a rescue for poor graft function after haematopoietic stem cell transplantation: A multicentre retrospective study on behalf of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC).
Gaffet M, Wiedemann A, Dalle JH, Bilger K, Forcade E, Robin M, Cornillon J, Labussière-Wallet H, Ceballos P, Bulabois CE, Loschi M, Orvain C, Rubio MT, Neven B, Pagliuca S, Pochon C. Gaffet M, et al. Among authors: orvain c. Br J Haematol. 2023 Jun;201(6):1153-1158. doi: 10.1111/bjh.18744. Epub 2023 Mar 27. Br J Haematol. 2023. PMID: 36974355
Relationship between comorbidities, mutational profile, and outcome after intensive chemotherapy in patients older than 60 years with acute myeloid leukemia: Assessment of different risk scores.
Bachelot A, Bouvier A, Riou J, Thepot S, Giltat A, Nunes Gomes C, Paillassa J, Jouanneau-Courville R, Renard M, Beucher A, Cottin L, Wiber M, Ribourtout B, Geneviève F, Luque Paz D, Tanguy-Schmidt A, Ugo V, Hunault-Berger M, Blanchet O, Orvain C. Bachelot A, et al. Among authors: orvain c. Am J Hematol. 2023 Jun;98(6):922-931. doi: 10.1002/ajh.26917. Epub 2023 Apr 5. Am J Hematol. 2023. PMID: 36964937
Outcome of patients with newly diagnosed AML admitted to the ICU, including preemptive admission - a multi-center study.
Desprez C, Kouatchet A, Marchand T, Mear JB, Tadié JM, Peterlin P, Chevalier P, Canet E, Couturier MA, Guillerm G, Bodenes L, Gyan E, Villate A, Ehrmann S, Lebreton A, Lester MA, Fronteau C, Larhantec G, André V, Riou J, Hunault-Berger M, Schmidt-Tanguy A, Orvain C. Desprez C, et al. Among authors: orvain c. Ann Hematol. 2023 Jun;102(6):1383-1393. doi: 10.1007/s00277-023-05205-6. Epub 2023 Apr 11. Ann Hematol. 2023. PMID: 37039874
Gilteritinib activity in refractory or relapsed FLT3-mutated acute myeloid leukemia patients previously treated by intensive chemotherapy and midostaurin: a study from the French AML Intergroup ALFA/FILO.
Dumas PY, Raffoux E, Bérard E, Bertoli S, Hospital MA, Heiblig M, Desbrosses Y, Bonmati C, Pautas C, Lambert J, Orvain C, Banos A, Pasquier F, Peterlin P, Marchand T, Uzunov M, Frayfer J, Turlure P, Cluzeau T, Jourdan E, Himberlin C, Tavernier E, Villate A, Haiat S, Chretien ML, Carre M, Chantepie S, Vaida I, Wemeau M, Chebrek S, Guillerm G, Guièze R, Debarri H, Gehlkopf E, Laribi K, Marcais A, Santagostino A, Béné MC, Mineur A, Pigneux A, Dombret H, Récher C. Dumas PY, et al. Among authors: orvain c. Leukemia. 2023 Jan;37(1):91-101. doi: 10.1038/s41375-022-01742-7. Epub 2022 Nov 14. Leukemia. 2023. PMID: 36376378 Free article.
First-line second generation tyrosine kinase inhibitors in patients with newly diagnosed accelerated phase chronic myeloid leukemia.
Balsat M, Alcazer V, Etienne G, Huguet F, Berger M, Cayssials E, Charbonnier A, Escoffre-Barbe M, Johnson-Ansah H, Legros L, Roy L, Delmer A, Ianotto JC, Orvain C, Larosa F, Meunier M, Amé S, Andreoli A, Cony-Makhoul P, Morisset S, Tigaud I, Rea D, Nicolini FE. Balsat M, et al. Among authors: orvain c. Leuk Res. 2023 Jul;130:107308. doi: 10.1016/j.leukres.2023.107308. Epub 2023 May 9. Leuk Res. 2023. PMID: 37230027
Toxicity Profile According to Etoposide and Cytarabine Dosing in Patients with Lymphoma Receiving Autologous Stem Cell Transplantation Following BEAM Conditioning.
Vely A, Paillassa J, Nunes Gomes C, Giltat A, Fouquet S, Lebreton A, Klemencie M, Clavert A, Tanguy-Schmidt A, Hunault-Berger M, Orvain C. Vely A, et al. Among authors: orvain c. Ann Hematol. 2023 Aug;102(8):2225-2231. doi: 10.1007/s00277-023-05333-z. Epub 2023 Jun 28. Ann Hematol. 2023. PMID: 37380715
126 results